Cargando…

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

BACKGROUND: The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Gordon, Belkoff, Laurence, Hafron, Jason M., Saltzstein, Daniel R., Potdar, Rushikesh, Bhaumik, Amitabha, Phillips, Jennifer, McGowan, Tracy, Shore, Neal D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928932/ https://www.ncbi.nlm.nih.gov/pubmed/36472728 http://dx.doi.org/10.1007/s11523-022-00932-8

Ejemplares similares

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
por: De La Cerda, Jose, et al.
Publicado: (2023)

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
por: Saad, Fred, et al.
Publicado: (2023)

Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Correction to: Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
por: Lukes, Andrea, et al.
Publicado: (2023)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Hypothyroidism caused by apalutamide
por: Daviduck, Quinn, et al.
Publicado: (2023)

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
por: Shore, Neal D., et al.
Publicado: (2020)

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

A case of lichenoid drug eruption associated with relugolix
por: Han, Joseph, et al.
Publicado: (2023)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
por: Tatenuma, Tomoyuki, et al.
Publicado: (2023)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
por: Eberli, Daniel, et al.
Publicado: (2022)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Apalutamide‐associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy
por: Tohi, Yoichiro, et al.
Publicado: (2021)

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer
por: Honda, Tomoko, et al.
Publicado: (2022)

Psoriatic Skin Lesions after Apalutamide Treatment
por: MIYAGAWA, Fumi, et al.
Publicado: (2022)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
por: Smith, Matthew R., et al.
Publicado: (2016)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
por: Sasamori, Yukifumi, et al.
Publicado: (2021)

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists
por: Fragkoulis, Charalampos, et al.
Publicado: (2021)

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
por: Wada, Yoshimitsu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h3vn11jrcpuiei80heufgcqei4